Wednesday February 26 10:45 AM EST
Cypros Pharmaceutical Corp says drug helps heart
CARLSBAD, Calif., Feb 26 (Reuter) - Cypros Pharmaceutical Corp Wednesday said the results of a 47-patient, open-label, Phase II,
physician-sponsored trial of fructose-1, 6-diphosphate showed the drug has significant effects on heart muscle function in coronary
artery disease patients.
In a statement, the company said the drug significantly improved a number of indices of left ventricular function in patients with
impaired resting heart function (left ventricular end diastolic pressure) but had less effect in patients with normal resting heart
function.
The company said the results indicate a potential new use for the drug as a novel, positive inotrope that is selective for those patients
with moderate to severe impairments of heart function. The current study will be published in a peer review cardiology journal, and
the company has filed two patents filed covering the use of CPC-111 as a novel, positive inotrope.
Positive inotropes are drugs that increase the force of heart muscle contraction and thereby improve blood flow in patients with
compromised heart function.
Back to Cypros Pharmaceutical Corp news page |
